- Hide quoted text — Show quoted text -

<ccough…@REMOVE-TO-DELETE-UCSD.EDU> wrote:
>Our local pumper’s club had its annual ADA scientific meeting update
>by one of the local endocrinologist last night.  A couple of the
>highlights.  This is based on my inadequate notes and faulty memory of
>what is always a session punctuated with many questions that tends to
>interrupt narrative clarity.

>For the type 2s – Progress continues apace on the analogs to GLIP-I
>(Glucagon Like Peptide I).  GLIP-I increases insulin output,
>regenerates damaged beta cells, slows glucose absorption into the
>blood, and causes weight loss.  Diabetics show loss of production of
>GLIP-I.  The down side of GLIP-I is that it is short lived.  A shot
>starts working in 10 minutes and it is gone in an hour.  Everybody and
>their grandmother are looking for long acting analogs.  Farthest in
>the pipeline is Exenatide (the famous lizard spit peptide) for which
>phase 3 trial data was released at the meeting.  The results include
>reductions in A1c of 1 to 1.5 points, continued weight loss through 52
>weeks, no additional hypoglycemia, and beta cell regeneration.  
>Treatment requires 2 subcutaneous shots/day.  Roll out is expected in
>June 2005.  Wide use in the type 2 community is expected.  Several
>other analogs are starting trials including one that binds to albumin
>but remains active and one with a few amino acids switched that
>doesn’t break down.  Others are working on inhibiting the breakdown
>mechanism with some success.

>Type 1 & 2 – Many (most?, all?) complications appear to ultimately
>result from oxidation problems in the mitochondria.  New very powerful
>antioxidants are in the works.  Vitamin C and E are useless in this
>regard.  In fact, they are strongly contraindicated in diabetics
>taking statins.  Prospective trials have shown C and E to counter the
>secondary beneficial actions of statins.

>Type 1 & 2 – DIAD Trial (Detection of Ischemia in Asymptomatic
>Patients With Diabetes) 75-80% of diabetics die of adverse
>cardiovascular events.  50% of those have no chest pain to trigger
>emergency call.  For 1/3, death is the result of their first
>cardiovascular event.  DIAD is an attempt to find those at risk who
>are missed because they do not show symptoms.  The diagnostic test is
>a stress heart scan.  20% of those scanned have a clear cardio
>vascular problem.  1/3 of those have a major problem which requires
>treatment, e.g. stent placement.  There will be 4 more years of follow
>up to see if the detection and treatment result in improvements in
>mortality.  The presenter is screening all his 50+ year old diabetics
>every 2 years.  If you are clear in the stress heart scan, you have a
>very low chance of a problem in the following 2 years.

Thanks so much for that Charly.

Cheers, Alan, T2 d&e, Australia.
Remove weight and carbs to email.
—
Everything in Moderation – Except Laughter.

>Thanks for a very interesting post!

I second the gratitude!  Very helpful.

Priscilla

–
Ed
 T2  04/99   Starlix & Glucophage